{"contentid": 488156, "importid": NaN, "name": "Amzell acquires Swiss firm Bazell Pharma", "introduction": "Dutch specialist pharmaceutical development company Amzell has acquired Bazell Pharma, a high-end clinical development and R&D laboratory facility based in Allschwil, Switzerland, to help to accelerate its development pipeline of late-stage novel drug candidates.", "content": "<p>Dutch specialist pharmaceutical development company Amzell has acquired Bazell Pharma, a high-end clinical development and R&amp;D laboratory facility based in Allschwil, Switzerland, to help to accelerate its development pipeline of late-stage novel drug candidates.</p>\n<p>Amzell specializes in developing well-characterized active substances through to proof-of-concept or registration for sale to commercial partners. Amzell&rsquo;s innovative platforms and drug delivery technologies provide effective drug delivery, increased efficacy, and improved safety and compliance.</p>\n<p>Financial terms of the transaction have not been revealed.</p>\n<p>Amzell&rsquo;s chief executive, Dario Carrara, comments: &ldquo;We are very pleased to have finalized the acquisition of Bazell Pharma, as these lab facilities will be highly significant for the new candidates we have coming through our development pipeline. As our two lead candidates, AMZ001 for osteoarthritis of the knee, and AMZ002 for infantile epileptic disease, have now reached Phase III trials, we are able to accelerate the development of some of our earlier stage candidates.&rdquo;</p>\n<p>Alan Harris chairman of Amzell will also become chairman of Bazell Pharma while Dario Carrara will become CEO of Bazell Pharma.</p>", "date": "2021-03-25 16:49:00", "meta_title": "Amzell acquires Swiss firm Bazell Pharma", "meta_keywords": "Amzell,  Bazell Pharma, Acquisition, Development, Pipeline, AMZ001, AMZ002, Osteoarthritis, Epilepsy", "meta_description": "Amzell acquires Swiss firm Bazell Pharma", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-25 16:48:11", "updated": "2021-03-25 16:56:21", "access": NaN, "url": "https://www.thepharmaletter.com/article/amzell-acquires-swiss-firm-bazell-pharma", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "merger-large.jpg", "image2id": "merger-small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Anti-Arthritics/Rheumatics, CNS Diseases, Neurological", "topic_tag": "One to Watch Companies, Research", "geography_tag": "Netherlands, Switzerland", "company_tag": "Amzell, Bazell Pharma", "drug_tag": "AMZ001, AMZ002", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-25 16:49:00"}